Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin

被引:7
|
作者
Carmichael, AR
Tate, G
King, RFG
Sue-Ling, HM
Johnston, D
机构
[1] Leeds Gen Infirm, Acad Dept Surg, Leeds, W Yorkshire, England
[2] Leeds Gen Infirm, Dept Haematol, Leeds, W Yorkshire, England
关键词
obesity; fibrinolysis; fibrinogen; insulin;
D O I
10.1159/000057287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA), fibrinogen and insulin were measured in 43 patients 3 years after they had undergone the Magenstrasse and Mill (MM) procedure and in 43 morbidly obese (MO) patients. Mean plasma PAI-1 was 61 ng/ml in the MO group compared to 30 ng/ml in the MM group (p < 0.0001); mean plasma t-PA was 10 ng/ml in the MO group compared to 7 ng/ml in the MM group (p < 0.001). Mean fibrinogen was 3.6 g/l in the MO group compared to 3.2 g/l in the MM group (p < 0.05). Mean plasma insulin levels were 32 U/ml in the MO group compared to 15 U/ml in the MM group. These changes suggest that use of the MM procedure may reduce mortality and morbidity from coronary heart disease in these high-risk obese patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 50 条
  • [41] PLASMA CHANGES OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 DURING CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OTTANI, F
    GALVANI, M
    NICOLINI, FA
    RONCHI, A
    FERRINI, D
    RUSTICALI, F
    CIRCULATION, 1993, 88 (04) : 320 - 320
  • [42] Role of plasminogen activator and plasminogen activator inhibitor type-1 in luteolysis - a minireview
    Liu, YX
    Chen, YJ
    Feng, QA
    Hu, ZY
    CHINESE SCIENCE BULLETIN, 1997, 42 (23): : 1994 - 2000
  • [44] GENE INACTIVATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    STASSEN, JM
    KIECKENS, L
    VANNUFFELEN, A
    DEMOL, M
    COLLEN, D
    MULLIGAN, R
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 764 - 764
  • [45] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND TISSUE-TYPE PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX ARE RECOGNIZED BY DIFFERENT RECEPTOR SYSTEMS IN THE LIVER
    KUIPER, J
    OTTER, M
    VANZONNEVELD, AJ
    RIJKEN, DC
    VANBERKEL, TJC
    CIRCULATION, 1993, 88 (04) : 366 - 366
  • [46] CYTOKINE ACTIVATION OF VASCULAR ENDOTHELIUM - EFFECTS ON TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR
    SCHLEEF, RR
    BEVILACQUA, MP
    SAWDEY, M
    GIMBRONE, MA
    LOSKUTOFF, DJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1988, 263 (12) : 5797 - 5803
  • [47] Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation
    Ma, XL
    Huang, WY
    She, MP
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 1998, 66 : S57 - S64
  • [48] Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis
    Akenami, FOT
    Koskiniemi, M
    Mustjoki, S
    Siren, V
    Farkkila, M
    Vaheri, A
    FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 (02): : 109 - 113
  • [49] Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study
    A.J. Simpson
    N.A. Booth
    N.R. Moore
    S.J. Lewis
    R.S. Gray
    Acta Diabetologica, 1999, 36 : 155 - 158
  • [50] Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study
    Simpson, AJ
    Booth, NA
    Moore, NR
    Lewis, SJ
    Gray, RS
    ACTA DIABETOLOGICA, 1999, 36 (03) : 155 - 158